Comparative Pharmacology
Head-to-head clinical analysis: EXSEL versus NIZORAL ANTI DANDRUFF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXSEL versus NIZORAL ANTI DANDRUFF.
EXSEL vs NIZORAL ANTI-DANDRUFF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Exsel (selenium sulfide) is an antifungal agent that reduces the production of cutaneous oils and exerts cytostatic effects on epidermal cells. It inhibits the growth of Pityrosporum ovale and other fungi by interfering with oxidative enzyme systems, leading to decreased sebum production and normalization of epidermal turnover.
Ketoconazole, an imidazole antifungal agent, inhibits fungal cytochrome P450 14α-demethylase (CYP51), preventing the conversion of lanosterol to ergosterol, an essential component of fungal cell membranes. This disrupts membrane integrity and function.
1-2 mg orally once daily; maximum dose 2 mg/day.
Apply to wet hair, lather, and leave on for 3-5 minutes before rinsing. Use twice weekly for 4 weeks, then as needed to control dandruff.
None Documented
None Documented
Terminal half-life: 12-18 hours (mean 15 h); requires dose adjustment in renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is biphasic: initial 2 hours, terminal 8 hours (range 6-10 hours). After topical application, systemic absorption is minimal, resulting in an effective half-life of 72-96 hours in skin.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites.
Primarily fecal (57%) via biliary excretion as unchanged drug and metabolites; renal excretion accounts for approximately 13% (2-4% unchanged).
Category C
Category C
Topical Antifungal
Topical Antifungal